Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Pfizer (NY: PFE)
37.65 USD  UNCHANGED
Official Closing Price  /  Updated: 8:04 PM EDT, Jul 17, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,404
Open 37.46
Bid (Size) 37.52 (200)
Ask (Size) 37.77 (900)
Prev. Close 37.65
Today's Range 37.45 - 37.77
52wk Range 32.32 - 39.43
Shares Outstanding 5,849,571,048
Dividend Yield 3.56%
Performance
YTD
+3.32%
+3.32%
1 Month
+4.12%
+4.12%
3 Month
+3.63%
+3.63%
6 Month
+2.87%
+2.87%
1 Year
+13.23%
+13.23%
Top News
More News
Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
Pfizer Inc.(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an... Read More
from Business Wire News Releases
Novartis Earnings Top; CEO Says 'Prudent' Not To Raise Drug Prices
Novartis beat Q2 earnings views Wednesday. The Swiss giant said it's "prudent" not to raise U.S. drug prices now. Pfizer recently backtracked on price hikes under pressure from President Trump. Read More
from Investor's Business Daily
More News
Read More
Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
from Business Wire News Releases
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
from PR Newswire
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
from Business Wire News Releases
Why Biopharma Is Bracing For Drug-Pricing Woes In Second Quarter
from Investor's Business Daily
How Pfizer-Trump Game Of Chicken Could Play Out For Drug Prices
from Investor's Business Daily
UPDATE 3-Novartis joins Pfizer in halting U.S. drug price hikes
category companyNews
from Reuters: Company News
UPDATE 2-Novartis puts brakes on price hikes, bowing to U.S. pressure
category companyNews
from Reuters: Company News
3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure
from Investor's Business Daily
Johnson & Johnson CEO defends drug prices, calls for changes in how medical costs are covered
category Johnson & Johnson , People/Newsmakers/Donald Trump , Health Care/Pharmaceuticals Biotechnology and Life Sciences/Pharmaceuticals , and 11 more.
from CNBC.com News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X